Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.

@article{Ritchie2006DrugTA,
  title={Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.},
  author={Marylyn DeRiggi Ritchie and David W. Haas and Alison A. Motsinger and John P. Donahue and Huso Erdem and Stephen P. Raffanti and Peter F. Rebeiro and Alfred L. George and Richard B. Kim and Jonathan L. Haines and Timothy R Sterling},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2006},
  volume={43 6},
  pages={
          779-82
        }
}
  • M. Ritchie, D. Haas, +8 authors T. Sterling
  • Published 15 September 2006
  • Medicine, Biology
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenz- or nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C-->T (odds ratio, 0.254; P=.021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82% accuracy (P<.001). 
View on PubMed
academic.oup.com
101 Citations
Highly Influential Citations
3
Background Citations
25
Results Citations
4

101 Citations

Citation Type

Citation Type

Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.
  • D. Haas, J. Bartlett, +8 authors R. Kim
  • Medicine, Psychology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2006
TLDR
This work explored associations between MDR1, CYP2B6, and CYP3A polymorphisms and nevirapine hepatotoxicity and found that among participants in a randomized study in South Africa (FTC-302), MDR 1 3435C-->T was significantly associated with decreased risk of hepatot toxicity.
Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors.
TLDR
CYP2B6 genetic variants are important determinants of efavirenz and nevirapine pharmacokinetics and further studies are needed to identify the associations of CYP2B 6 genetic variants with the development of NNRTI resistant viruses.
Effect of host genetic variation on the pharmacokinetics and clinical response of NNRTIs
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.
TLDR
Genetic variability in CYP2B6 and CAR contributes to early treatment discontinuation for efavirenz-based antiretroviral regimens, and further studies are required to define the clinical utility of these associations.
PHARMACOGENETIC BASED DRUG-DRUG INTERACTIONS BETWEEN HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) AND ANTIBLASTIC CHEMOTHERAPY
TLDR
The purpose of this review is to summarize existing data on the impact of individual pharmacogenetic profile in order to optimize the clinical management of cancer patients with HIV/AIDS and between antiretrovirals and AC.
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
TLDR
This is the first report that the 983T>C genotype (part of the CYP2B6*18 haplotype) impacts on nevirapine plasma concentrations and the first study to assess the impact of 983C homozygosity on efavirenz concentrations.
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children
TLDR
The data suggest that the CYP2B6-G516T is an important genetic variant that alters the pharmacokinetics and response to HAART regimens containing NVP.
Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population
The aim of the study was to characterize the impact of the cytochrome P450 2B6 (CYP2B6), CYP3A4, CYP3A5 and ATP‐binding cassette sub‐family B member 1 (ABCB1) polymorphisms on nevirapine plasma…
HIV Integrase Inhibitor Pharmacogenetics: An Exploratory Study
TLDR
There is a need for further assessment, within the population living with HIV, of factors contributing to unfavorable subject outcomes, and several associations between variables and SNPs, when using INSTIs are discovered.
The Pharmacogenetics of HIV Treatment: A Practical Clinical Approach
TLDR
In this review, the most relevant genetic polymorphisms affecting the activity and/or the expression of key drug-metabolizing enzymes and membrane drug transporters are summarized.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 15 REFERENCES
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.
  • D. Haas, J. Bartlett, +8 authors R. Kim
  • Medicine, Psychology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2006
TLDR
This work explored associations between MDR1, CYP2B6, and CYP3A polymorphisms and nevirapine hepatotoxicity and found that among participants in a randomized study in South Africa (FTC-302), MDR 1 3435C-->T was significantly associated with decreased risk of hepatot toxicity.
Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients
TLDR
CYP2B6 genotyping may be useful to complement an individualization strategy based on plasma drug determinations to increase the safety and tolerability of EFV.
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
Differential Modulation of P-Glycoprotein Expression and Activity by Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors in Cell Culture
TLDR
NRTIs show differential effects on P-gp activity and expression in vitro, and clinical studies are required to elucidate the clinical importance of potential drug interactions.
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.
TLDR
Genetic variants predict plasma exposure to efavirenz and nelfinavir, and they may predict virologic failure and/or emergence of drug-resistant virus.
Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.
TLDR
The use of nevirapine in female patients with a low BMI should be discouraged and the occurrence of early hepatotoxicity was 17% in the ne virapine group and 0% inThe efavirenz group and was balanced between the lamivudine and emtricitabine arms.
Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus‐infected individuals
Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts
TLDR
It is suggested that HLA-DRB1*0101 and the CD4 status may determine susceptibility to nevirapine hypersensitivity, consistent with a CD4 T-cell-dependent immune response to ne virapine-specific antigens.
A Comprehensive Hepatic Safety Analysis of Nevirapine in Different Populations of HIV Infected Patients*
TLDR
Use of nevirapine was not associated with a significantly increased risk of clinical hepatotoxic events, including liver failure or liver related death, compared to therapy with other antiretroviral drugs.
...
1
2
...